298 related articles for article (PubMed ID: 9721869)
21. The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status.
Crespo NC; Delarue F; Ohkanda J; Carrico D; Hamilton AD; Sebti SM
Cell Death Differ; 2002 Jul; 9(7):702-9. PubMed ID: 12058275
[TBL] [Abstract][Full Text] [Related]
22. Expression of wild-type p53 increases etoposide cytotoxicity in M1 myeloid leukemia cells by facilitated G2 to M transition: implications for gene therapy.
Skladanowski A; Larsen AK
Cancer Res; 1997 Mar; 57(5):818-23. PubMed ID: 9041178
[TBL] [Abstract][Full Text] [Related]
23. Protein phosphatase 2A interacts with Chk2 and regulates phosphorylation at Thr-68 after cisplatin treatment of human ovarian cancer cells.
Liang X; Reed E; Yu JJ
Int J Mol Med; 2006 May; 17(5):703-8. PubMed ID: 16596250
[TBL] [Abstract][Full Text] [Related]
24. IC261, a specific inhibitor of the protein kinases casein kinase 1-delta and -epsilon, triggers the mitotic checkpoint and induces p53-dependent postmitotic effects.
Behrend L; Milne DM; Stöter M; Deppert W; Campbell LE; Meek DW; Knippschild U
Oncogene; 2000 Nov; 19(47):5303-13. PubMed ID: 11103931
[TBL] [Abstract][Full Text] [Related]
25. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors.
Ishida R; Miki T; Narita T; Yui R; Sato M; Utsumi KR; Tanabe K; Andoh T
Cancer Res; 1991 Sep; 51(18):4909-16. PubMed ID: 1654205
[TBL] [Abstract][Full Text] [Related]
27. Berberine, a genotoxic alkaloid, induces ATM-Chk1 mediated G2 arrest in prostate cancer cells.
Wang Y; Liu Q; Liu Z; Li B; Sun Z; Zhou H; Zhang X; Gong Y; Shao C
Mutat Res; 2012 Jun; 734(1-2):20-9. PubMed ID: 22561209
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
29. Fostriecin: a review of the preclinical data.
de Jong RS; de Vries EG; Mulder NH
Anticancer Drugs; 1997 Jun; 8(5):413-8. PubMed ID: 9215602
[TBL] [Abstract][Full Text] [Related]
30. Okadaic acid overcomes the blocked cell cycle caused by depleting Cdc2-related kinases in Trypanosoma brucei.
Li Z; Tu X; Wang CC
Exp Cell Res; 2006 Nov; 312(18):3504-16. PubMed ID: 16949574
[TBL] [Abstract][Full Text] [Related]
31. Altered centrosomes in ataxia-telangiectasia cells and rapamycin-treated Chinese hamster cells.
Bonatti S; Simili M; Benedetti PA; Morandi F; Menichini P; Del Carratore R; Barale R; Abbondandolo A
Environ Mol Mutagen; 2005 Oct; 46(3):164-73. PubMed ID: 15920752
[TBL] [Abstract][Full Text] [Related]
32. Induction of apoptosis by the garlic-derived compound S-allylmercaptocysteine (SAMC) is associated with microtubule depolymerization and c-Jun NH(2)-terminal kinase 1 activation.
Xiao D; Pinto JT; Soh JW; Deguchi A; Gundersen GG; Palazzo AF; Yoon JT; Shirin H; Weinstein IB
Cancer Res; 2003 Oct; 63(20):6825-37. PubMed ID: 14583480
[TBL] [Abstract][Full Text] [Related]
33. Fostriecin: chemistry and biology.
Lewy DS; Gauss CM; Soenen DR; Boger DL
Curr Med Chem; 2002 Nov; 9(22):2005-32. PubMed ID: 12369868
[TBL] [Abstract][Full Text] [Related]
34. Suppression of Ser/Thr phosphatase 4 (PP4C/PPP4C) mimics a novel post-mitotic action of fostriecin, producing mitotic slippage followed by tetraploid cell death.
Theobald B; Bonness K; Musiyenko A; Andrews JF; Urban G; Huang X; Dean NM; Honkanen RE
Mol Cancer Res; 2013 Aug; 11(8):845-55. PubMed ID: 23671329
[TBL] [Abstract][Full Text] [Related]
35. Treatment of myeloid leukemic cells with the phosphatase inhibitor okadaic acid induces cell cycle arrest at either G1/S or G2/M depending on dose.
Ishida Y; Furukawa Y; Decaprio JA; Saito M; Griffin JD
J Cell Physiol; 1992 Mar; 150(3):484-92. PubMed ID: 1311329
[TBL] [Abstract][Full Text] [Related]
36. Downregulation of protein phosphatase 2A activity in HeLa cells at the G2-mitosis transition and unscheduled reactivation induced by 12-O-tetradecanoyl phorbol-13-acetate (TPA).
Klingler-Hoffmann M; Barth H; Richards J; König N; Kinzel V
Eur J Cell Biol; 2005 Aug; 84(8):719-32. PubMed ID: 16180310
[TBL] [Abstract][Full Text] [Related]
37. Structure-activity relationship studies of fostriecin, cytostatin, and key analogs, with PP1, PP2A, PP5, and( beta12-beta13)-chimeras (PP1/PP2A and PP5/PP2A), provide further insight into the inhibitory actions of fostriecin family inhibitors.
Swingle MR; Amable L; Lawhorn BG; Buck SB; Burke CP; Ratti P; Fischer KL; Boger DL; Honkanen RE
J Pharmacol Exp Ther; 2009 Oct; 331(1):45-53. PubMed ID: 19592665
[TBL] [Abstract][Full Text] [Related]
38. Biochemical differences between staurosporine-induced apoptosis and premature mitosis.
Yoshida M; Usui T; Tsujimura K; Inagaki M; Beppu T; Horinouchi S
Exp Cell Res; 1997 May; 232(2):225-39. PubMed ID: 9168797
[TBL] [Abstract][Full Text] [Related]
39. Genistein arrests cell cycle progression at G2-M.
Matsukawa Y; Marui N; Sakai T; Satomi Y; Yoshida M; Matsumoto K; Nishino H; Aoike A
Cancer Res; 1993 Mar; 53(6):1328-31. PubMed ID: 8443813
[TBL] [Abstract][Full Text] [Related]
40. Cdc2-independent induction of premature mitosis by okadaic acid in HeLa cells.
Ghosh S; Paweletz N; Schroeter D
Exp Cell Res; 1998 Jul; 242(1):1-9. PubMed ID: 9665796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
